Half-year Financial Report

Summary by AI BETAClose X

Scancell Holdings plc reported interim results for the six months ended 31 October 2025, with an operating loss of £8.9 million, an improvement from £10.5 million in the prior year, and a cash balance of £8.6 million. The company's lead product, iSCIB1+, demonstrated a 74% Progression Free Survival at 16 months in advanced melanoma, leading to FDA clearance for a Phase 3 trial planned to commence in 2026. Modi-1 data for head and neck and renal cell cancer is anticipated in H1 2026, and the company has established GlyMab Therapeutics Limited to focus on antibody assets. The company expects its cash runway to extend to H2 2026.

Disclaimer*

UK 100

Latest directors dealings